RenovoRx (NASDAQ:RNXT) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

RenovoRx (NASDAQ:RNXT) issued its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01), FiscalAI reports. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 135.11%. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.06 million.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx reported record third-quarter revenue of $1.07 million, up 17% sequentially and more than fourfold year over year, and maintained full-year 2026 revenue guidance of $3.75 million to $4.25 million.
• Active commercial cancer centers increased from 21 to 26, with more than 40 additional centers in the evaluation, approval, or activation pipeline. Management reiterated its year-end target of 36 active centers and cited repeat orders from most existing customers as a source of demand.
• Enrollment is complete in the Phase III TIGeR-PaC trial, with initial top-line results expected in the second half of 2027; the trial is evaluating targeted gemcitabine delivery against standard systemic therapy. Results are not yet available, and the timing leaves a substantial wait for a key clinical milestone.
• The company reported early expansion efforts beyond locally advanced pancreatic cancer, including a commercial sarcoma treatment and the first patient treated in a University of Vermont investigator-led trial of pre-surgical TAMP. These applications remain exploratory.
• RenovoRx posted a $3.6 million quarterly net loss, while SG&A rose to $2.9 million from $1.7 million a year earlier as it built commercial infrastructure. Cash was $10.4 million at quarter-end, which management said should fund operations into the second half of 2027; the balance included $3.5 million from warrant exercises.

RenovoRx Stock Performance

Shares of NASDAQ:RNXT traded down $0.06 during midday trading on Friday, reaching $1.13. 1,845,235 shares of the company’s stock were exchanged, compared to its average volume of 462,472. The firm has a market capitalization of $51.00 million, a PE ratio of -3.65 and a beta of 1.12. RenovoRx has a 12 month low of $0.70 and a 12 month high of $2.59. The company’s 50 day simple moving average is $1.55 and its two-hundred day simple moving average is $1.11.

Analyst Ratings Changes

RNXT has been the subject of several research reports. Wall Street Zen raised RenovoRx from a “sell” rating to a “hold” rating in a research note on Sunday, November 1st. Weiss Ratings upgraded RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, RenovoRx presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

About RenovoRx

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.